Developing a Prediction Model for Determination of Peanut Allergy Status in the Learning Early About Peanut Allergy (LEAP) Studies

Accepted/In Press date: 12 April 2023

e-pub ahead of print date: 3 May 2023

Published date: 1 July 2023

Additional Information: Funding Information: This research was performed as a project of the Immune Tolerance Network , an international clinical research consortium headquartered at the Benaroya Research Institute, and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award no. UM1AI109565 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Conflicts of interest: G. Roberts reports grants from the National Institute of Allergy and Infectious Diseases (NIAID, National Institutes of Health [NIH]). G. du Toit reports grants from NIAID (NIH), Food Allergy & Research Education (FARE), MRC & Asthma UK Centre, UK Department of Health through the National Institute for Health and Care Research (NIHR), and Action Medical Research and National Peanut Board; is a scientific advisory board member of Aimmune; is an investigator on pharma-sponsored allergy studies (Aimmune and DBV Technologies); and is a scientific advisor to Aimmune, DBV, and Novartis. H. T. Bahnson reports contract work paid to the institution, Benaroya Research Institute, from DBV Technologies, MYOR, King’s College London, and Stanford University; and additional salary support paid by King’s College London and Stanford University. S. Radulovic reports salary support from grants from NIAID (NIH). D. Larson reports employment compensation from Horizon Therapeutics. A. F. Santos reports grants from the Medical Research Council, the National Institute for Health Research, and NIAID; grants pending with Asthma UK, Medical Research Council, Biotechnology and Biological Sciences Research Council, and Rosetrees Trust; consultancy from Allergy Therpeutics, Stallergenes, and IgGenix; paid speaker services for Thermofisher, Buhlmann, Infomed, Nutricia, and Nestle; and provision of reagents through collaboration with King's College London and Thermofisher and Buhlmann. G. Lack reports grants from NIAID (NIH) and other from FARE, MRC & Asthma UK Centre, UK Department of Health through NIHR, National Peanut Board (NPB), and the Davis Foundation, during the conduct of the study; is a shareholder in DBV Technologies and Mighty Mission Me; and reports personal fees from Novartis, Sanofi-Genyzme, Regeneron, ALK-Abello, and Lurie Children's Hospital, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Publisher Copyright: © 2023 The Authors

Keywords: Diagnostic algorithm, Food allergy, LEAP, Peanut allergy, Prevention

Local EPrints ID: 478867

URI: http://eprints.soton.ac.uk/id/eprint/478867

DOI: doi:10.1016/j.jaip.2023.04.032

ISSN: 2213-2198

PURE UUID: 88968758-18ea-45c3-b6cf-0906c52e0eeb

ORCID for Graham Roberts: orcid.org/0000-0003-2252-1248

Date deposited: 11 Jul 2023 17:16

Last modified: 17 Mar 2024 03:02